Premium
Myocardial energetics and ubiquinol in diastolic heart failure
Author(s) -
Bates Angelina,
Shen Qiuhua,
Hiebert John B.,
Thimmesch Amanda,
Pierce Janet D.
Publication year - 2014
Publication title -
nursing and health sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.563
H-Index - 47
eISSN - 1442-2018
pISSN - 1441-0745
DOI - 10.1111/nhs.12168
Subject(s) - ubiquinol , heart failure , medicine , diastolic heart failure , ejection fraction , heart failure with preserved ejection fraction , cardiology , diastole , coenzyme q10 , oxidative stress , stroke volume , mitochondrion , blood pressure , chemistry , coenzyme q – cytochrome c reductase , biochemistry , cytochrome c
Diastolic heart failure, or heart failure with preserved ejection fraction, is a leading cause of morbidity and mortality. There are no current therapies effective in improving outcomes for these patients. The aim of this article is to review the literature and examine the role of coenzyme Q 10 in heart failure with preserved ejection fraction related to mitochondrial synthesis of adenosine triphosphate and reactive oxygen species production. The study results reflect that myocardial energetics alters in diastolic heart failure and that there is defective energy metabolism and increased oxidative stress. Studies are emerging to evaluate coenzyme Q 10 , particularly ubiquinol, as a supplemental treatment for heart‐failure patients. In diastolic heart‐failure patients, clinicians are beginning to use supplemental therapies to improve patient outcomes, and one promising complementary treatment to improve left ventricular diastolic function is ubiquinol. Additional studies are needed using large‐scale randomized models to confirm if ubiquinol would be beneficial. Since ubiquinol is an antioxidant and is required for adenosine triphosphate production, clinicians and health scientists should be aware of the potential role of this supplement in the treatment of diastolic heart failure.